Integrin Alpha V Market
Integrin Alpha V Market Size, Share & Trends Analysis Report By Type (MK-0429, C-16Y, 264-RAD, AC-301, and Others), By Application (Metabolic Disorders, Ophthalmology, Respiratory, Infectious Disease, and Others) Forecast Period, (2026-2035)
Industry Overview
Integrin alpha V market valued at $2,015.6 million in 2025 and is projected to reach $3,351.6 million by 2035, growing at a CAGR of 5.8% during the forecast period (2026-2035). The global integrin alpha V market is advancing steadily as research and therapeutic development increasingly focus on targeted molecular pathways involved in oncology, fibrosis, and inflammatory disorders. Growth is being reinforced by expanding clinical investigation into integrin alpha V inhibitors and monoclonal antibodies designed to regulate cell adhesion, migration, and angiogenesis. Rising interest in precision medicine and biomarker-driven treatment approaches is further strengthening demand for integrin-focused therapeutics. As regulatory agencies emphasize targeted biologics and pathway-specific interventions, integrin alpha V–based therapies are becoming increasingly relevant in next-generation drug development strategies.
Market Dynamics
Growing Emphasis on Targeted Oncology and Fibrosis Therapies
Integrin alpha V plays a critical role in tumor progression, metastasis, and tissue remodeling, prompting significant research activity across oncology and fibrotic disease segments. Pharmaceutical companies are advancing monoclonal antibodies, peptide inhibitors, and small molecules aimed at modulating integrin-mediated signaling pathways. The expanding understanding of tumor microenvironment interactions is encouraging integration of integrin alpha V inhibitors into combination therapy strategies. As precision oncology continues to evolve, demand for pathway-specific biologics targeting integrin alpha V is expected to strengthen.
Increasing Clinical Pipeline Activity and Biologic Innovation
The market is being supported by a growing pipeline of investigational therapies targeting integrin alpha V receptors across multiple indications. Advances in antibody engineering, drug conjugation technologies, and biologic formulation are enhancing therapeutic specificity and safety profiles. Biotechnology firms are collaborating with research institutions to accelerate translational development and clinical validation. These developments are contributing to a more robust innovation ecosystem and reinforcing long-term commercial potential within the market.
Market Segmentation
- Based on the Type, the market is segmented into MK-0429, C-16Y, 264-RAD, AC-301, and others.
- Based on the application, the market is segmented into metabolic disorders, ophthalmology, respiratory, infectious disease, and others.
MK-0429 Segment to Lead the Market with the Largest Share
MK-0429 is anticipated to account for a significant share of the global integrin alpha V market, supported by its advanced stage of clinical evaluation and broad therapeutic potential. As a selective integrin ?v antagonist, MK-0429 has demonstrated promising results in targeting fibrosis and related pathological pathways, making it a strong candidate across multiple disease indications. Its extensive research backing and structured development pipeline position it as a key asset among integrin alpha V–targeting therapies. Continued clinical progress, strategic collaborations, and growing interest in anti-fibrotic and anti-inflammatory mechanisms are expected to reinforce MK-0429’s leading market position.
Metabolic Disorders: A Key Application Driving Market Growth
The metabolic disorders segment is projected to be a major contributor to market growth, owing to the increasing global burden of conditions such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and other metabolic-linked complications. Integrin alpha V plays a critical role in tissue remodeling and fibrotic signaling pathways, making it an attractive therapeutic target in metabolic disease management. Rising awareness, expanding clinical research activities, and the growing need for disease-modifying treatments are accelerating demand within this segment. As pharmaceutical companies intensify efforts to address unmet needs in metabolic disorders, this application area is expected to remain a central driver of expansion in the integrin alpha V market.
Regional Outlook
The global integrin alpha V market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Expanding Research Investments Across Asia-Pacific
Asia-Pacific is witnessing rising research investment in molecular-targeted therapies, including integrin pathway modulation. Academic institutions and biotechnology startups are increasingly participating in early-stage discovery programs supported by government-backed funding initiatives. Growing clinical trial activity and improved regulatory pathways for biologics are further supporting regional engagement. As the region strengthens its biotechnology infrastructure, it is emerging as a meaningful contributor to global integrin alpha V research and commercialization efforts.
North America Region Dominates the Market with Major Share
North America maintains a leading position in the integrin alpha V market, driven by a strong biopharmaceutical ecosystem and high levels of R&D expenditure. The presence of established biotechnology firms and advanced clinical research networks supports rapid development and testing of novel targeted therapies. Regulatory support for innovative biologics and orphan indications further enhances commercialization prospects. Combined with increasing adoption of precision medicine approaches, these factors reinforce North America’s significant market share.
Market Players Outlook
The major companies operating in the global integrin alpha V market include AbbVie Inc., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In July 2025, Merck KGaA announced the advancement of its integrin alpha inhibitor into Phase II clinical trials for idiopathic pulmonary fibrosis, strengthening its pipeline in fibrosis-focused targeted therapies.
- In March 2025, Pliant Therapeutics reported positive interim data from its ongoing clinical program evaluating an integrin inhibitor for liver fibrosis, highlighting continued momentum in integrin-targeted drug development.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global integrin alpha V Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Integrin Alpha V Market Sales Analysis – Type | Application ($ Million)
- Integrin Alpha V Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Integrin Alpha V Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Integrin Alpha V Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Integrin Alpha V Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Integrin Alpha V Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Integrin Alpha V Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Integrin Alpha V Market Revenue and Share by Manufacturers
- Integrin Alpha V Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Amgen Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AstraZeneca plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche Ltd
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AbbVie Inc.
- Key Company Analysis
- Global Integrin Alpha V Market Sales Analysis by Type ($ Million)
- MK-0429
- C-16Y
- 264-RAD
- AC-301
- Others
- Global Integrin Alpha V Market Sales Analysis by Application ($ Million)
- Metabolic Disorders
- Ophthalmology
- Respiratory
- Infectious Disease
- Others
- Regional Analysis
- North American Integrin Alpha V Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Integrin Alpha V Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Integrin Alpha V Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Integrin Alpha V Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbexa Ltd
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbiotec LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bio-Rad Laboratories, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bio-Techne Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CLOUD-CLONE CORP.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Gilead Sciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novus Biologicals, LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Vertex Pharmaceuticals Incorporated
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbexa Ltd
1. Global Integrin Alpha V Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global MK-0429 Integrin Alpha V Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global C-16Y Integrin Alpha V Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global 264-RAD Integrin Alpha V Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global AC-301 Integrin Alpha V Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Others Integrin Alpha V Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Integrin Alpha V Market Research and Analysis by Application, 2025–2035 ($ Million)
8. Global Integrin Alpha V For Metabolic Disorders Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Integrin Alpha V For Ophthalmology Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Integrin Alpha V For Respiratory Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Integrin Alpha V For Infectious Disease Nephritis Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Integrin Alpha V For Others Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Integrin Alpha V Market Research and Analysis by Region, 2025–2035 ($ Million)
14. North American Integrin Alpha V Market Research and Analysis by Country, 2025–2035 ($ Million)
15. North American Integrin Alpha V Market Research and Analysis by Type, 2025–2035 ($ Million)
16. North American Integrin Alpha V Market Research and Analysis by Application, 2025–2035 ($ Million)
17. European Integrin Alpha V Market Research and Analysis by Country, 2025–2035 ($ Million)
18. European Integrin Alpha V Market Research and Analysis by Type, 2025–2035 ($ Million)
19. European Integrin Alpha V Market Research and Analysis by Application, 2025–2035 ($ Million)
20. Asia-Pacific Integrin Alpha V Market Research and Analysis by Country, 2025–2035 ($ Million)
21. Asia-Pacific Integrin Alpha V Market Research and Analysis by Type, 2025–2035 ($ Million)
22. Asia-Pacific Integrin Alpha V Market Research and Analysis by Application, 2025–2035 ($ Million)
23. Rest of the World Integrin Alpha V Market Research and Analysis by Region, 2025–2035 ($ Million)
24. Rest of the World Integrin Alpha V Market Research and Analysis by Type, 2025–2035 ($ Million)
25. Rest of the World Integrin Alpha V Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global Integrin Alpha V Market Share by Type, 2025 Vs 2035 (%)
2. Global MK-0429 Integrin Alpha V Market Share by Region, 2025 Vs 2035 (%)
3. Global C-16Y Integrin Alpha V Market Share by Region, 2025 Vs 2035 (%)
4. Global 264-RAD Integrin Alpha V Market Share by Region, 2025 Vs 2035 (%)
5. Global AC-301 Integrin Alpha V Market Share by Region, 2025 Vs 2035 (%)
6. Global Others Integrin Alpha V Market Share by Region, 2025 Vs 2035 (%)
7. Global Integrin Alpha V Market Research and Analysis by Application, 2025 Vs 2035 (%)
8. Global Integrin Alpha V for Metabolic Disorders Market Share by Region, 2025 Vs 2035 (%)
9. Global Integrin Alpha V for Ophthalmology Market Share by Region, 2025 Vs 2035 (%)
10. Global Integrin Alpha V for Respiratory Market Share by Region, 2025 Vs 2035 (%)
11. Global Integrin Alpha V for Infectious Disease Nephritis Market Share by Region, 2025 Vs 2035 (%)
12. Global Integrin Alpha V for Others Market Share by Region, 2025 Vs 2035 (%)
13. Global Integrin Alpha V Market Research and Analysis by Region, 2025–2035 ($ Million)
14. US Integrin Alpha V Market Size, 2025–2035 ($ Million)
15. Canada Integrin Alpha V Market Size, 2025–2035 ($ Million)
16. UK Integrin Alpha V Market Size, 2025–2035 ($ Million)
17. France Integrin Alpha V Market Size, 2025–2035 ($ Million)
18. Germany Integrin Alpha V Market Size, 2025–2035 ($ Million)
19. Italy Integrin Alpha V Market Size, 2025–2035 ($ Million)
20. Spain Integrin Alpha V Market Size, 2025–2035 ($ Million)
21. Russia Integrin Alpha V Market Size, 2025–2035 ($ Million)
22. Rest of Europe Integrin Alpha V Market Size, 2025–2035 ($ Million)
23. India Integrin Alpha V Market Size, 2025–2035 ($ Million)
24. China Integrin Alpha V Market Size, 2025–2035 ($ Million)
25. Japan Integrin Alpha V Market Size, 2025–2035 ($ Million)
26. South Korea Integrin Alpha V Market Size, 2025–2035 ($ Million)
27. Australia and New Zealand Integrin Alpha V Market Size, 2025–2035 ($ Million)
28. ASEAN Economies Integrin Alpha V Market Size, 2025–2035 ($ Million)
29. Rest of Asia-Pacific Integrin Alpha V Market Size, 2025–2035 ($ Million)
30. Latin America Integrin Alpha V Market Size, 2025–2035 ($ Million)
31. Middle East and Africa Integrin Alpha V Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Integrin Alpha V Market in 2025 is estimated to be around $2,015.6 million.
North America holds the largest share in the Integrin Alpha V Market.
Leading players in the Integrin Alpha V Market include AbbVie Inc., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, Pfizer Inc., among others.
The Integrin Alpha V Market is expected to grow at a CAGR of 5.8% from 2026 to 2035.
The Integrin Alpha V Market growth is driven by increasing research in cancer and fibrotic diseases and rising development of targeted integrin-based therapeutic therapies.
